494 related articles for article (PubMed ID: 15899831)
1. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
[TBL] [Abstract][Full Text] [Related]
2. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
5. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
8. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
10. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Smith NR; James NH; Oakley I; Wainwright A; Copley C; Kendrew J; Womersley LM; Jürgensmeier JM; Wedge SR; Barry ST
Mol Cancer Ther; 2007 Aug; 6(8):2198-208. PubMed ID: 17699717
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
13. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
14. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
[TBL] [Abstract][Full Text] [Related]
15. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
16. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
18. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
